Experimental CAR T-Cell therapy targets rare testicular cancer
NCT ID NCT05634785
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a new treatment for nonseminomatous germ cell tumors (a type of testicular cancer) that had not responded to standard therapy. The treatment used the patient's own immune cells (T cells) that were genetically modified to recognize and attack cancer cells carrying the CD30 protein. Only 2 people took part, and the main goal was to see if the tumors shrank. The study also collected blood and tumor samples to learn more about how the modified cells work in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD30-targeted CAR T-cells (ATLCAR.CD30 cells) plus cyclophosphamide
What this could lead to
If it works, this could point toward a new treatment option for hard-to-treat germ cell tumors.
What could go wrong
This was a very small, early-phase trial with only 2 participants, so results are not conclusive. The treatment may not shrink tumors or could cause side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599, United States